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Inflammatory bowel disease (IBD) constitutes a severe intestinal disorder in developed countries with increasing incidence worldwide.
Upcoming evidence indicates an important role of intestinal epithelial barrier function in the development of IBD. Fatty acids exert nutritional and
protective effects on enterocytes, serve as activators of transcription and constitute precursors of inflammatory mediators. The aim of this study
was to investigate differential regulation of genes involved in fatty acid uptake and endogenous fatty acid biosynthesis in IBD. Mucosal biopsy
specimens from non-affected regions of the intestine were subjected to DNA microarray analysis. Gene array analysis revealed a variety of genes
involved in fatty acid uptake and synthesis to be differentially expressed in ileum and colon of selected IBD patients. To verify these results, real-
time RT-PCR was performed for selected regulated candidate genes in larger IBD sample numbers. In single biopsy analysis long chain acyl-CoA
synthetase (ACSL) 1 and 4 were upregulated in IBD (Pb0.05), while a significant decrease in fatty acid synthase expression was found in ileum
and colon of ulcerative colitis patients (Pb0.001). Expression of the transcription factor liver X receptor (LXR) which was previously shown to
induce fatty acid synthase gene expression was not altered on mRNA level in IBD. However, in cell culture experiments using the human
intestinal cell line LS174T induction of fatty acid synthase by the LXR ligand T0901317 was inhibited by TNFα. Moreover, these experiments
indicated a decrease of LXR protein levels by TNFα treatment. These data suggest that the decrease of fatty acid synthase expression in ulcerative
colitis patients could be at least partially due to a loss of LXR expression and function in the presence of pro-inflammatory cytokines. Observed
alterations in expression of genes of fatty acid metabolism may contribute to the pathophysiology of ulcerative colitis.
© 2005 Elsevier B.V. All rights reserved.Keywords: Fatty acid transport; Fatty acid synthase; Inflammatory bowel disease; Cytokine; Liver X receptor1. Introduction
Many aspects of the multifactorial etiology and pathogenesis
of inflammatory bowel diseases (IBD), ulcerative colitis (UC)
and Crohn's disease (CD), still remain poorly understood. In
addition to some identified genetic factors, such as the NOD2
gene [1,2], it is assumed that exaggerated immune responses to
the normal gut microflora involving CD4+ T-cells are mainly
responsible for initiation and perpetuation of chronic intestinal
inflammation [1]. In particular, secretion of proinflammatory
molecules such as TNFα obviously play a central role in the
pathogenesis of IBD, since the blockade of TNF with specific
antibodies has been shown to be an effective treatment in CD⁎ Corresponding author. Tel.: +49 941 944 6201; fax: +49 941 944 6202.
E-mail address: gerd.schmitz@klinik.uni-regensburg.de (G. Schmitz).
0925-4439/$ - see front matter © 2005 Elsevier B.V. All rights reserved.
doi:10.1016/j.bbadis.2005.12.006[2,3]. However, there is upcoming evidence that the intestinal
epithelial cell itself plays an important role in triggering local
immune responses, as well as in providing a barrier function
between the intestinal lumen and immune cells [4]. Therefore,
the integrity and function of the intestinal epithelium seems to
constitute an important factor in the development of IBD. A
wide range of different fatty acids are essential factors for
enterocyte physiology and inflammatory processes [5,6].
Short-chain fatty acids (SCFA), in particular butyrate, which
is produced in the gut by microbial fermentation of carbohy-
drates and endogenous substrates [7], such as mucus, serve as
important energy source for colonic mucosal cells. Beneficial
effects of SCFA on inflamed colonic mucosa including UC have
been demonstrated [8], while a lack of butyrate can result in
intestinal inflammation [9]. The mechanisms underlying the
protective role of SCFA are not fully understood so far. Butyrate
Table 1
Patient information
Disease
activity
Non-
IBD
Crohn's disease Ulcerative colitis
Active Inactive Active Inactive
n 16 8 5 16 3
Sex (M/F) 8/8 3/5 2/3 11/5 2/1
Age (years)
Range 22–69 23–59 36–74 20–72 33–38
mean 47.2 41.7 57.2 39.1 35.3
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including detoxification of xenobiotics [10] and mucus
synthesis [11]. In addition, butyrate has been described to
reduce colonic paracellular permeability by enhancing perox-
isome proliferator-activated receptor γ (PPARγ) activation
[12].
Besides SCFA, long chain fatty acids considerably
contribute to enterocyte function and pathology. In particular,
polyunsaturated fatty acids (PUFA), such as ω-3 and ω-6
PUFA, are able to modulate inflammatory processes. In IBD,
beneficial effects of ω-3 fatty acids like eicosapentaenoic acid
and docosahexaenoic acid have been shown in several clinical
trials [13]. ω-3 fatty acids were demonstrated to affect tight
junction permeability of intestinal epithelial cells [14] and to
decrease oxidative stress in UC patients [15]. By competing
with ω-6 fatty acids, eicosapentaenoic acid inhibits the
production of arachidonic acid metabolites like leukotriene
B4 and prostaglandin E2 via the 5-lipoxygenase pathway
[16]. However, prostaglandin E2 and its receptor EP4,
attenuate dextran sodium sulphate-induced (DSS) colitis in
animal models by reducing the levels of mucosal inflamma-
tory cytokines and suppressing T-cell activation in the gut
[17–19]. Recently, conjugated linoleic acid (CLA), a class of
positional, geometric, conjugated dienoic isomers of linoleic
acid was also demonstrated to ameliorate DSS colitis in a
mouse model by activation of PPARγ resulting in repression
of tumor necrosis factor α (TNFα) expression and NFκB
activation, while the immunoregulatory cytokine transforming
growth factor β (TGFβ) was induced [20]. In UC patients,
PPARγ displayed a diminished expression in colonic
epithelial cells [21] and reversal of reduced PPARγ
expression in mice with DSS-induced colitis markedly
attenuated disease activity [22].
Although increasing evidence indicates an important role of
fatty acids and PPARγ in health and pathology of the intestinal
mucosa, alterations of fatty acid metabolism itself are only
poorly understood so far. Therefore, we here addressed the
question, how intestinal fatty acid uptake as well as fatty acid
synthesis and metabolism are altered in the intestinal epithelium
of IBD patients. Therefore, the expression of fatty acid transport
proteins (FATP), fatty acid binding proteins (FABP), long chain
acyl-CoA synthetases (ACSL) as well as genes involved in
endogenous fatty acid synthesis were analyzed in intestinal
epithelial cells of IBD patients.
2. Material and methods
2.1. Patients and tissue specimens
Approval conduct to the study was obtained from the Ethics Committee of
the University of Regensburg. Samples for real-time RT-PCR were derived from
biopsies taken from terminal ileum and colon from 13 patients with Crohn's
disease, 19 patients with ulcerative colitis and 16 control patients, who
underwent coloscopy for other reasons than IBD, including tumor staging (Table
1). In 11 patients of the control group coloscopy revealed no tissue
abnormalities, two patients had diverticulosis, one patient diverticulitis and
two patients suffered from infectious colitis. All diagnoses of IBD patients were
based on classical clinical features, radiological, endoscopic and laboratory
findings. Disease activity was based on endoscopic criteria. A special diet wasnot administered. Patients were fasting for at least 12 h before coloscopy. IBD
tissue biopsies from non-inflamed regions 10 cm distant from pathological area
were selected and sampled by a specialized gastroenterologist. Biopsies were
immediately stabilized in RNAlater solution (Qiagen, Hilden, Germany) and
kept at −80 °C until isolation of RNA.
2.2. RNA isolation
Total RNA was extracted from the tissue biopsies or cultured cell lines
according to the manufacturer's instructions using the RNeasy Protect midi Kit
(Qiagen, Hilden, Germany). Purity and integrity of the RNAwas assessed on the
Agilent bioanalyzer with the 6000 Nano LabChip reagent set (Agilent
Technologies, USA). The RNA was quantified spectrophotometrically and
then stored at −80 °C.
2.3. Cell culture
The human adenocarcinoma cell line LS174T was obtained from ATCC
(Manassas, USA). Cells were grown in Dulbecco's Modified Eagle medium
supplemented with 10% heat-inactivated fetal calf serum, 2 mmol/l glutamine
and 1% (wt/vol) penicillin/streptomycin (Gibco BRL, Gaithersburg, MD, USA).
Cultures were maintained at 37 °C in a humidified 5% CO2 atmosphere. Cells
were stimulated for 24 h with 100 ng/ml human recombinant TNFα expressed in
E. coli (Sigma, St. Louis, USA), and/or 10 μM T0901317 (Sigma, St. Louis,
USA) or 10 μM rifampicin (Sigma, St. Louis, USA).
2.4. DNA microarray analysis
DNA microarray analysis was performed as described earlier [23]. Gene
expression profiles were determined using Affymetrix HGU133A and
HGU133B GeneChips covering 22238 annotated human genes and more than
33000 human EST sequences. Arrays were performed using a pool from total
RNA of four specimens from each patient and control group. Validation of
mucosal control genes indicated that the gene expression profiles of the analyzed
biopsy specimens mainly represent the global gene expression of epithelial cells
and that immune cells do not significantly contribute to the observed transcript
patterns [23]. Microarray data were deposited in the GEO database.
2.5. Real-time RT-PCR (TaqMan™) analysis
First-strand cDNA synthesis was performed with the Reverse Transcription
System from Promega (Madison, USA) according to the manufacturer's
instructions. Real-time RT-PCR analysis was performed with an ABI7900HT
machine (Applied Biosystems). All TaqMan RT-PCR reagents, including
primers and probes, were purchased from Applied Biosystems. TaqMan analysis
was performed with predesigned and optimized Assays on Demand (Applied
Biosystems). The following assays were used: CD36 (ID: Hs00169627_m1),
FATP1-6 (IDs: Hs00417419_g1, Hs00186324_m1, Hs00225680_m1,
Hs00192700_m1, Hs00202073_m1, Hs00204034_m1), FABP1-7 (IDs:
Hs00155026_m1, Hs00164552_m1, Hs00269758_m1, Hs00609791_m1,
Hs00870436_s1, Hs00155029_m1, Hs00361426_m1), FABP-PM (ID:
Hs00751057_s1), ACSL1 (ID: Hs00242530_m1), ACSL3-6 (IDs:
Hs00244853_m1, Hs00244871_m1, Hs00212106_m1, Hs00362960_m1),
fatty acid synthase (ID: Hs00188012_m1), IL-8 (ID: Hs00174103_m1), 18S
ribosomal RNA (ID: Hs99999901_s1), ABCA1 (ID: Hs00194045_m1),
Table 2
mRNA expression of FATPs, CD36, FABPs and ACSLs in terminal ileum and
colon of control specimens
Terminal ileum Colon
FATP1 ••• •••
FATP2 •••• •••
FATP3 •• ••
FATP4 •••• •••
FATP5 • not expressed
FATP6 • •
FAT/CD36 ••• •••
FABP-PM ••• •••
FABP1 ••••• •••••
FABP2 •••• ••••
FABP3 • ••
FABP4 •• ••
FABP5 ••• •••
FABP6 •••• ••
FABP7 not expressed •
ACSL1 ••• ••••
ACSL3 •••• ••••
ACSL4 ••• •••
ACSL5 •••• ••••
ACSL6 •• •
mRNA expression of FATPs, CD36, FABPs and ACSLs in terminal ileum and
colon of control specimens. Expression levels are represented as filled circles
and are based on delta ct levels. At least five different tissue specimens were
analyzed for each gene.
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Hs00748952_s1), SREBP1 (ID: Hs00231674_m1), LXRα and β (IDs:
Hs00172885_m1, Hs00173195_m1), TNF (Hs00174128_m1), NFκB1
(Hs00231653_m1), RelA (Hs00153294_m1), TGFβ1 (Hs99999918_m1). The
reaction parameters were as follows: 2-min 50 °C hold, 30-min 60 °C hold, and
5-min 95 °C hold, followed by 45 cycles of 20-s 94 °C melting and 1-min 60 °C
annealing/extension. Measurements were performed in duplicates or triplicates.
Results were analyzed with an ABI sequence detector software version 2.0
(Applied Biosystems). Relative quantitation was performed as described earlier
[24], and 18S ribosomal RNA (rRNA) was used as a reference gene. Since all
assays used were optimized for PCR efficiency by the manufacturer, mRNA
expression levels were estimated by delta ct values.
2.6. Immunoblotting
The following antibodies were used: rabbit anti-human fatty acid synthase
(Assay Designs, Michigan, USA), rabbit anti-human LXRα/β (H-144) (Santa
Cruz Biotechnology, Santa Cruz, USA), mouse anti-human villin (Chemicon
International, Hofheim, Germany). Cells were harvested, washed with PBS and
frozen (−20 °C). Cells were lysed by 0.02% SDS solution and sonicated (MSE
Soniprep 150, Beun de Ronde BV, Abcoude, The Netherlands). Equal amounts
of protein were analyzed by SDS-PAGE using 4–12% gels. After electropho-
resis, proteins were transferred to fluorotrans transfer membranes (Pall,
Dreieich, Germany). Membranes were then blocked by incubation for 1 h in
PBS containing 5% nonfat milk powder and 0.1% Tween 20. For detection of
individual proteins, membranes were incubated for 1 h with the corresponding
antibodies in a dilution of 1:1000 in PBS with 1% nonfat milk powder and 0.1%
Tween 20. Detection of immune complexes was carried out with the ECL plus
Western blot detection system (Amersham Pharmacia, Deisenhofen, Germany)
and analyzed with a Lumi-Imager (Roche Diagnostics, Mannheim, Germany).
2.7. Statistical analysis
All data are expressed as mean±S.D. Statistical analysis was performed
using SPSS 12.0 software. Statistical significance was determined by the Mann–
Whitney U test for biopsy data and the Student t test for paired samples for cell
culture experiments. The level of significance was corrected to Bonferroni to
compensate for the effect of multiple comparisons. A Pb0.05 was considered as
statistically significant.3. Results
3.1. mRNA expression of genes involved in fatty acid uptake
and activation in normal human terminal ileum and colon
Fatty acid uptake, cellular binding and activation to acyl-
CoA for subsequent metabolic conversion obviously play a
central role for enterocyte physiology. To evaluate the normal
mRNA expression pattern of these genes real-time RT-PCR was
performed for the FATP, FABP and ACSL family members
using RNA isolated from biopsies of 5–10 control specimens
taken from colon and terminal ileum. To compare the mRNA
expression of different genes in the two tissues, expression
levels are displayed as filled circles in Table 2, which are based
on delta ct values (ct (target gene) -ct (18S rRNA). A small
interindividual variability in gene expression was observed with
the exception of FABP6. Within the FATP family, FATP2 and
FATP4 displayed highest expression levels in terminal ileum
and in colon, whereas FATP5 and FATP6 were only weakly or
not expressed in both tissues. As expected from literature data,
FABP1 and FABP6 exhibited highest expression levels in the
ileum. However, considerable expression levels in this tissuewere also detected for FABP2, FABP5 and FABP-PM. In the
colon, FABP1 mRNAwas abundantly present, whereas FABP6
was clearly weaker expressed. In addition, we found significant
mRNA expression signals for FABP2, FABP5 and FABP-PM.
Considerable mRNA amounts for ACSL1, ACSL3, ACSL4 and
ACSL 5 were detected in both tissues. Weaker expression levels
were detected for ACSL6. These data clearly show a substantial
expression of several genes needed for effective fatty acid
uptake and synthesis mechanisms in intestine. In particular,
FATP4, FABP1, FABP2 and ACSL1, 3 and 4 were highly
expressed.
3.2. Genes involved in fatty acid metabolism are differentially
regulated in IBD
We next addressed the question whether these genes
involved in fatty acid metabolism were differentially regulated
in IBD. In order to obtain the global mRNA expression profiles
of all these genes, pooled RNAs of biopsies from terminal ileum
and colon taken from four CD and UC patients and controls,
respectively, were subjected to DNA microarray analysis and
further evaluated using a biomedical pathway approach.
Probesets detecting FATP2–6 and CD36, FABP1–7, ACSL1,
ACSL3–6 as well as genes and regulators of fatty acid synthesis
were present on the array. Estimating basal gene expression
levels from array probeset data, highest expression levels were
found for FABP1 and FABP6 which was consistent with real-
time RT-PCR results. Several genes, including FATP5, FATP6,
FABP3, FABP4, and FABP7 could not be detected by the array
(Table 2).
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expression (fold change: up to 4.0 and up to 2.5) in colon of CD
and UC patients. In contrast, fatty acid synthase was decreased
in the colon of IBD patients (up to −5.7 fold). Moreover, the
transcriptional master regulator of fatty acid synthesis, sterol
regulatory element-binding protein 1 (SREBP1), was down-
regulated in the colon of CD and UC patients (−2.1 fold and
−2.8 fold, respectively). The differential regulations were also
observed in the ileum and colon of CD patients, but to a lower
extent. No change could be observed for the mRNA expression
of the transcription factors liver X receptor (LXR) α and β,
which were previously shown to modulate the expression of
fatty acid synthase as well as of SREBP1 [25–27] (Table 3). To
confirm these findings from DNA microarrays, we performedTable 3
Expression and regulation of genes involved in fatty acid metabolism and TNFα sig
Gene RefSeq Control expression of ileum FC
Fatty acid transport and binding
FATP2 NM_003645 188 1.
FATP3 BC003654 88 − 1.
FATP4 AK000722 415 1.
FATP5 AL042852 n.e.
FATP6 NM_014031 n.e.
FAT/CD36 AW299226 153 2.
FABP-PM NM_002080 423 − 1.
FABP1 NM_001443 5545 − 1.
FABP2 NM_000134 46 1.
FABP3 AI219891 n.e.
FABP4 NM_001442 n.e.
FABP5 NM_001444 596 − 1.
FABP6 U19869 5666 − 1.
FABP7 NM_001446 n.e.
Fatty acid acetylation
ACSL1 NM_021122 33 1.
ACSL3 AL525798 159 1.
ACSL4 NM_022977 11 1.
ACSL5 AW173691 3499 − 1.
ACSL6 AL390168 25 1.
Fatty acid synthesis
Fatty acid synthase AI954041 110 − 2.
LCE NM_024090 112 1.
SCD AB032261 166 1.
SREBP1 NM_004176 127 1.
SCAP NM_012235 185 − 1.
LXRα NM_005693 128 1.
LXRβ NM_007121 53 − 1.
TNFα signaling
TNF NM_000594 n.e.
TNF receptor-1A NM_001065 596 1.
TNF receptor-1B NM_001066 81 − 1.
FADD NM_003824 74 1.
TRADD L41690 57 − 1.
IKKβ AU153366 106 1.
IKKγ NM_003639 213 − 1.
IKAP NM_001556 97 1.
NFKB1 M55643 208 − 1.
TGF-β1 BC000125 62 − 1.
Expression and regulation of genes involved in fatty acid uptake, activation, and in f
control expression values are given for the terminal ileum and the colon. Genes with a
given cell type. The fold change (FC) of gene expression between controls and patiquantitative real-time RT-PCR analysis in a larger number of
single unpooled and unrelated biopsy specimens (4–14
independent samples for each patient group) for selected
genes. Single biopsy analysis revealed a significant increase
of ACSL1 and ACSL4 expression in the ileum and colon of
both, CD and UC patients (Pb0.05) (Fig. 1A, B). In addition,
real-time RT-PCR revealed a down-regulation of fatty acid
synthase gene expression in terminal ileum and colon of UC
patients (Pb0.001) (Fig. 1C). A tendency showing a decrease of
SREBP1 expression in the colon of UC patients could be
observed (Fig. 1D).
To evaluate if an impaired expression of LXR isoforms was
responsible for the observed loss of fatty acid synthase and
SREBP1 gene expression in UC we investigated the expressionnaling in CD or UC samples compared with control specimens
CD FC UC Control expression of colon FC CD FC UC
5 1.1 185 1.1 1.0
3 1.3 108 − 1.6 − 1.4
6 − 1.3 413 − 2.3 − 4.9
n.e..
n.e.
8 1.3 127 2.3 1.1
1 − 1.4 453 1.0 1.0
6 − 1.5 4867 1.1 1.0
5 − 1.1 76 − 1.9 − 4.9
n.e.
n.e.
3 − 2.2 1068 1.1 1.1
3 − 1.1 3545 − 1.1 − 10.6
n.e.
1 1.2 88 1.7 4.0
5 − 1.1 190 1.7 1.3
6 1.1 25 1.7 2.5
1 − 1.1 2438 − 1.2 − 1.3
2 − 1.2 23 1.2 1.1
0 − 1.2 177 − 2.6 − 5.7
2 1.6 332 2.1 1.6
1 − 1.1 111 1.4 2.1
1 − 1.1 128 − 2.1 − 2.8
1 − 1.3 213 − 1.3 − 1.3
2 1.3 128 − 1.5 1.1
2 1.3 n.e.
n.e.
3 1.0 573 − 1.1 − 1.2
1 1.3 63 − 1.3 − 2.0
1 1.1 114 − 1.1 − 1.2
3 1.5 72 − 1.1 1.4
1 1.9 137 1.0 1.3
4 1.0 182 − 1.4 − 1.6
3 1.2 95 1.5 1.4
5 1.0 186 − 1.9 1.0
6 1.4 73 − 1.5 − 3.7
atty acid synthesis in CD or UC samples compared with control specimens. The
verage difference intensity of 50 are considered as significantly expressed in the
ent groups is indicated. n.e.: not expressed.
Fig. 1. mRNA expression of ACSL1 (A), ACSL4 (B), fatty acid synthase (C), SREBP1(D) and LXRα and β (E and F) in IBD biopsy specimens. Real-time RT-PCR
analysis both genes in ileal and colonic biopsy samples from control individuals (black circle) and CD (open triangle) and UC patients (open square). Transcript
abundance of analyzed genes was expressed as relative gene expression. Expression levels were normalized to 18S rRNA. Measurements were performed in duplicate.
The horizontal line indicates the mean gene expression value of each group. *Pb0.05 (CD or UC versus control), ***Pb0.001 (UC versus control).
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However, in accordance with gene array data, expression of
LXRα and LXRβ was not significantly altered in IBD (Fig.
1E, F).
The decrease of FATP4, CD36 and FABP6 gene expression
indicated by array analysis of pooled samples could not be
verified by real-time RT-PCR of single biopsies (data not
shown). Discrepancies may be due to interindividual scatter of
mRNA expression levels as well as to detection of certain
mRNA splice variants by the gene array.3.3. Effect of TNFα on LXR target gene expression in LS174T
cells
To elucidate underlying mechanisms of the strongly
decreased expression of fatty acid synthase in colitis patients
we investigated whether the down-regulation of LXR targets like
fatty acid synthase and SREBP1 could be potentially mediated
by pro-inflammatory cytokines, such as TNFα, or if ligand-
induced LXR activation could be altered by TNFα. We
incubated LS174T cells with human recombinant TNFα and/
346 S. Heimerl et al. / Biochimica et Biophysica Acta 1762 (2006) 341–350or the PXR ligand rifampicin or the synthetic LXR ligand
T0901317 for 24 h. After stimulation, mRNA levels of several
genes as well as fatty acid synthase protein levels were analyzed.
As positive controls, we selected IL-8, known to be upregulated
at the mRNA level in intestinal cell lines [28], and CYP3A4 thatFig. 2. Inhibition of LXR ligand-induced gene expression by TNFα. LS174T cells st
10 μMT0901317 for 24 h and gene expression of IL-8 (A), CYP3A4 (B), ABCA1 (C
and LXRβ (H)wasmonitored by real-timeRT-PCR. The results of RT-PCR analysis w
as reference gene. Results are shown as means±S.D. of 3 individual experiments. Mwas demonstrated to be induced by PXR ligands [23]. As
indicated in Fig. 2A, stimulation with TNFα caused a strong
increase in IL-8 mRNA expression. CYP3A4 was induced by
rifampicin stimulation and this effect was strongly inhibited by
addition of TNFα. We could also observe a strong upregulationimulated with human recombinant 100 ng/ml TNFα and/or 10 μM rifampicin or
) fatty acid synthase (D), SREBP1(E) and steoryl-CoA desaturase (F), LXRα (G)
ere expressed as relative gene expression and normalized to 18S rRNA expression
easurements were performed in triplicate. *Pb0.05 (TNFα versus control).
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rifampicin which is most likely due to PXR activation by
T0901317 [29]. Again, induction was inhibited by addition of
TNFα (Fig. 2B).
As expected, stimulation with T0901317 induced gene
expression of the analyzed LXR target genes ABCA1, fatty
acid synthase, steaoryl-CoA desaturase and SREBP1 after 24 h,
while rifampicin did not alter the expression of these genes.
Costimulation with T0901317 and TNFα clearly impaired the
LXR ligand-induced mRNA expression of ABCA1 and fatty
acid synthase (Fig. 2C, D). Inhibition of T0901317-induced fatty
acid gene expression could also be observed at the protein level
by immunoblotting (Fig. 3A). In tendency, the same regulation
was found for SREBP1, but not for steaoryl-CoA desaturase
(Fig. 2E, F). However, basal expression of these genes was not
influenced by TNFα.
In the same cell culture model, we investigated the
expression of LXRα and β. Similar to the gene expression
patterns in patient biopsies, LXRα and β mRNA expression
was not affected by stimulation with TNFα. However, TNFα
treatment reduced LXR protein levels in total cell lysate (Fig.
3B). These date indicate that in this cell type inflammatory
cytokines may mainly alter LXR translation and probably LXR
function, but not LXR mRNA expression.
3.4. Genes involved in TNFα signaling are not altered on the
mRNA level
Our cell culture experiments indicated a role of TNFα in
differential regulation of fatty acid synthase expression in UC
patients. Therefore, we additionally evaluated the mRNA
expression of genes of TNFα signal transduction in these
patients. TNF mRNA could not be detected by gene array
experiments and was found only weakly expressed by real-
time RT-PCR in analyzed biopsies (Table 3 and data not
shown). Moreover, microarray analysis did not indicateFig. 3. Inhibition of LXR expression and LXR ligand-induced fatty acid
synthase expression by TNFα. LS174T cells stimulated with human
recombinant 100 ng/ml TNFα and/or 10 μM T0901317 for 24 h and protein
expression of fatty acid synthase (A) and LXRα/β (B) was detected by SDS
page. Protein expression of villin was used as reference gene. Results of one
representative experiment are shown.differential regulation of genes involved in intestinal TNFα
signal transduction [30] ,including TNF receptor-1A and -1B,
Fas-associated death domain (FADD), TNF receptor-1-
associated death domain (TRADD), IκB kinase (IKK)-β
and -γ, IKK complex-associated protein (IKAP) and NFκB1
(Table 3). Array data for NFκB1 as well as RelA which was
not detected by the array were validated in single biopsies
(data not shown).
TGF-β1 expression was found decreased in colon of CD and
UC patients (−1.5 fold and −3.7 fold, respectively) by gene
array experiments. However, this result could not be verified by
real-time RT-PCR in single biopsies (data not shown).
4. Discussion
Fatty acids play an important role in inflammatory processes
as well as in ensuring nutrition and cellular integrity by
providing a molecular source for phospholipid synthesis.
Active uptake of long chain fatty acids involves FATPs (solute
carrier family 27 1–6). This family of integral transmembrane
proteins consists of six so far identified members which show
different tissue expression patterns [31]. Among these genes,
FATP4 has been identified as the major intestinal transport
protein that is expressed at high levels on the apical side of
mature enterocytes in the small intestine and is required for
efficient uptake of fatty acids by enterocytes, mainly palmitate
and oleate [32]. Our studies revealed in addition to FATP4 high
expression levels of FATP2, suggesting a significant role of this
transporter in intestinal tissues as well. Moreover, CD36 is well
characterized in facilitating fatty acid uptake in a variety of
tissues [33]. Although, data from CD36-deficient mice suggest
only a minor role of this transporter in enterocytes [34],
considerable mRNA amounts of CD36 were detected in the
analyzed ileum and colon biopsies from human samples.
Moreover, recent evidence by Drover et. al. indicates that
CD36 is important for secretion and clearance of intestinal
lipoproteins [35]. Therefore, a species difference cannot be
excluded.
Further mechanisms of intestinal absorption of long chain
fatty acids involve the family of FABPs which reversely bind
fatty acids after entering the cell for further fatty acid
metabolism. Besides the supply of fatty acids, FABPs may
also protect the cell against the detergent effects of free fatty acid
and bile acids. Seven different FABPs have been described so
far, however, major roles in the intestinal tissue have been
attributed only to FABP1 (L-FABP) that is preferentially
implicated in phospholipid synthesis, membrane protection
and gene regulation, FABP2 and FABP6 (gastropin, ileal)
[36,37]. This is in good accordance with our data detecting high
levels of FABP1, FABP2 and FABP6 in terminal ileum biopsies
and high mRNA amounts of FABP1 and FABP2 in colon
biopsies.
For further fatty acid metabolism acetylation of fatty acids by
ACSL is required. Five human ACSL isoforms have been
identified so far. Substrates of this enzyme family can enter a
variety of pathways including synthesis of fatty acids,
triacylglycerol and phospholipids, β-oxidation and cholesterol
348 S. Heimerl et al. / Biochimica et Biophysica Acta 1762 (2006) 341–350esterification. Interestingly, ACSL1 and 4 seem to provide acyl-
CoA destinated primarily for triacylglycerol and de-novo
synthesis of phospholipids, while β-oxidation is suggested to
rely on acyl-CoA synthesized by other isoforms [38]. In our
study, we found a significant increase of ACSL1 and ACSL4 in
terminal ileum and in colon of IBD patients. This implies that
enterocyte fatty acids may mainly enter the phospholipid
pathway in CD and UC patients, where they could serve as
precursors for inflammatory mediators. Moreover, phospholi-
pids may be incorporated into intestinal plasma membranes
supporting membrane integrity and epithelial barrier function of
the affected intestine. Therefore, upregulation of ACSL1 and
ACSL4 could be a compensatory mechanism for slowing
disease progression in IBD.
Besides fatty acid uptake, de-novo synthesis of long-chain
saturated and monounsaturated fatty acids significantly con-
tributes to the production of membrane phospholipids [39]. In
colorectal neoplasia both, the transcription factor SREBP1 and
fatty acid synthase are highly upregulated [40], most likely to
provide membrane phospholipids for these rapidly proliferating
cells [41,42]. SREBP1 plays a central role in regulating the
biosynthesis of proinflammatory mediators, as well as in
controlling the endogenous synthesis of saturated and mono-
unsaturated fatty acids, involving fatty acid synthase, long chain
fatty acyl elongase and stearoyl-CoA desaturase [43]. Fatty acid
synthase is the key enzyme of endogenous fatty acid synthesis
leading to palmitate (C16:0), stearic acid (C18:0) and oleic acid
(C18:1). Interestingly, Ehehalt et al. could demonstrate that the
most abundant phosphatidylcholine (PC) species in rectal
mucus were PC 16:0/18:1, PC 16:0/18:2, PC 18:0/18:1 and
PC 18:0/18:2 [44], of which almost all are potential products of
fatty acid synthase activity. In our analyzed biopsies we found a
highly significant decrease of fatty acid synthase expression in
ileum and colon of UC patients. Therefore, the finding that
patients with inactive UC showed significant less PC in rectal
mucus [44] explaining increased susceptibility of enterocytes,
may be a direct consequence of impaired fatty acid synthase
expression in these patients. Since the hydrophobic mucus layer
plays a key role in intestinal barrier properties [45], down-
regulation of fatty acid synthase may significantly contribute to
the pathophysiology of UC in this context.
However, the mechanisms leading to decreased fatty acid
synthase expression still remain unclear. In addition to SREBP1,
LXR significantly contributes to the transcriptional regulation of
endogenous fatty acid synthesis. In particular, SREBP1 [26,27],
fatty acid synthase and steaoryl-CoA desaturase are also induced
by LXR [25,46]. LXR belongs to the family of nuclear hormone
receptors which function as ligand-activated transcription
factors [47,48]. Transcriptional activity of these receptors
requires heterodimerization with the retinoid X receptor
(RXR) [49]. The two LXR isoforms, LXRα and LXRβ, are
well known to act as key regulators in sterol and fatty acid
metabolism, transactivating a variety of genes that govern
transport, catabolism and elimination of cholesterol. Different
oxysterols represent naturally occurring ligands for these
receptors [50]. In addition to its central role in lipid metabolism,
evidence also suggests an involvement of LXR in inflammatoryprocesses. In rodent liver, LPS treatment induces a decrease of
LXR expression, as well as of its heterodimerization partner
RXR [51] and significantly impairs mRNA levels of the LXR
targets ATP-binding cassette (ABC) transporter ABCG5 and
ABCG8 [52–54]. Both genes were also found to be down-
regulated in colon of UC patients [23]. In J774 murine
macrophages endotoxins or cytokines also resulted in a decrease
of ABCA1 and ABCG1 [52], two further LXR target genes
[55,56]. Moreover, in irritant and contact models of dermatitis,
LXR activators display potent anti-inflammatory activity
requiring the participation of LXRα and LXRβ [57].
In addition to LXR, further members of the nuclear hormone
receptor family have been implicated to the regulation of
inflammatory processes, in particular IBD, including PPARγ
and pregnane X receptor (PXR).
A recent study from our group could demonstrate a loss of
expression of the transcription factor PXR in epithelial cells of
colon of UC patients compared with control specimens. This
down-regulation was accompanied by a decreased expression of
a set of PXR target genes, including ABCB1 (MDR1), mainly
involving cellular detoxification and defense [23].
Because of the growing evidence that nuclear hormone
receptors play, an important role in inflammatory processes, we
here addressed the question, if LXR-induced fatty acid synthase
activation was impaired by inflammatory mediators, such as
TNFα. Although TNFα signaling showed no transcriptional
changes in IBD, an induction of this pathway by other
mechanisms cannot be excluded. The finding that TNF
mRNA was only weakly expressed and not differentially
regulated in analyzed biopsies emphasizes the role of recruited
immune cells as source of proinflammatory cytokines in IBD
[30].
Using cell culture model for intestinal epithelial cells we
found a significant reduction of LXR mediated fatty acid
synthase expression upon stimulation with TNFα. mRNA
expression of LXRα and LXR β remained unaffected under
these conditions while we observed decreased protein expres-
sion potentially involved down-regulation of fatty acid
synthase. However, further studies are required to elucidate
underlying mechanisms in this context as well as functional
aspects, e.g. alterations in nuclear translocation. Nevertheless,
our results do not fully explain the observed strongly down-
regulated fatty acid synthase mRNA expression in biopsies of
UC patients. These findings suggest that the loss of fatty acid
synthase expression in UC may in part be due to a loss of LXR
protein expression and also LXR function in an inflamed
environment, but seems to be additionally caused by unknown
mechanisms.
In summary, we here identified considerable alterations in
the expression of genes involved in intestinal fatty acid
metabolism in IBD patients. The observed changes in the
expression pattern of genes involved in fatty acid uptake,
metabolism and synthesis may be partially a consequence of
inflammation, but also seem to contribute substantially to the
pathophysiology of the disease. However, further investigation
including measurement of enzyme activities and lipid analysis
will be needed to elucidate causative pathomechanisms.
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